Monday, October 5, 2026

OpenAI's Chief Scientist Predicts Entire Research Labs Will Operate Inside Data Centers

OpenAI Chief Scientist Jakub Pachocki says AI models are approaching the ability to work indefinitely like human researchers, enabling fully automated research labs housed in data centers. The development coincides with 68 new AI unicorns emerging in early 2026, but raises governance challenges that Pachocki admits industry cannot solve alone.

LM Salvado

March 23, 2026

OpenAI's Chief Scientist Predicts Entire Research Labs Will Operate Inside Data Centers
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

OpenAI Chief Scientist Jakub Pachocki predicts AI models will soon enable "a whole research lab in a data center," with systems capable of conducting research autonomously for extended periods.1

"I think we are getting close to a point where we'll have models capable of working indefinitely in a coherent way just like people do," Pachocki said.1 The shift stems from capability improvements that allow models to operate longer without human intervention, moving beyond current limitations on autonomous task completion.1

The infrastructure requirements for this transformation are substantial. Pachocki advocates deploying the most powerful models in isolated sandboxes, disconnected from systems they could damage or exploit.1 This approach reflects growing concern about AI systems with extended operational autonomy.

The prediction arrives as AI infrastructure investment accelerates. Early 2026 saw 68 companies reach unicorn status in the sector,2 while established players make strategic moves—S&P Global acquired energy AI firm Enertel AI to strengthen analytics capabilities. The venture capital landscape supporting these developments shows concentration among specialized investors backing this new unicorn class.2

Pachocki acknowledges the governance gap created by autonomous AI researchers. "I think this is a big challenge for governments to figure out," he said, recognizing that industry self-regulation proves insufficient for systems operating at research-lab scale.1

The competitive implications extend beyond OpenAI. Automated research capabilities could compress development timelines across AI labs, potentially accelerating the pace of breakthroughs while concentrating research capacity among organizations with sufficient computational resources. The data center model favors players with infrastructure scale, raising questions about research access and capability distribution.

Adjacent developments in quantum computing applications for healthcare and enterprise AI deployments suggest the broader technology landscape is preparing for more autonomous systems. However, the regulatory frameworks Pachocki identifies as necessary remain undeveloped, creating a temporal gap between technical capability and governance readiness.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleMIT Technology Review
    OpenAI is throwing everything into building a fully automated researcher
  2. [2]News articleYahoo Finance· January 22, 2026
    4 Medical Supply Stocks Poised to Gain in a Prospering Industry
  3. [3]News articleYahoo Finance· February 24, 2026
    Agentic AI Foundation Welcomes 97 New Members As Demand for Open, Collaborative Agent Standardization Increases
  4. [4]Press releaseGlobeNewswire· March 13, 2026
    Agero Enters into Agreement to Acquire Urgently, for $5.50 in Cash Per Share, Expanding Tech-Driven Roadside Assistance Across Automotive, Fleet, Rental, and Insurance Markets
  5. [5]News articleYahoo Finance· November 26, 2025
    AI to Reshape the Global Technology Landscape in 2026, Says TrendForce
  6. [6]News articleMIT Technology Review
    Can quantum computers now solve health care problems? We’ll soon find out.
  7. [7]News articleYahoo Finance· January 30, 2026
    Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
  8. [8]News articleYahoo Finance· March 19, 2026
    Morning Brief: 3 big questions, 2 answers, and rate cut hopes remain alive
  9. [9]News articleYahoo Finance· March 17, 2026
    Nebius Teams With NVIDIA to Build Cloud for Robotics and Physical AI
  10. [10]News articleYahoo Finance· March 18, 2026
    S&P Global Acquires Enertel AI Corporation to Enhance Power Market Offering
  11. [11]News articleCrunchbase News
    The Rising Investors Behind The New Unicorn Class
  12. [12]Press releaseGlobeNewswire· March 19, 2026
    Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com